In Brief: Quintiles
Quintiles: Definitive agreement to acquire CerebroVascular Advances announced by Research Triangle Park, N.C.-based Quintiles May 8. Quintiles will issue 251,000 shares valued at approximately $14 mil. to fund the acquisition. The merger is expected to be completed later this year. Quintiles said that it expects to retain CVA CEO David Edwards and Chief Operating Officer Mike Dwyer. San Antonio-based CVA is a clinical research company specializing in stroke trials and had net income of $1.3 mil. on revenues of $4.5 mil. in 1996...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth